Literature DB >> 16713688

Differentiation between field and vaccine strain of bluetongue virus serotype 16.

F Monaco1, C Cammà, S Serini, G Savini.   

Abstract

In August 2000, bluetongue virus (BTV) appeared for the first time in Sardinia and, since then, the infection spread across Sicily and into the mainland of Italy involving at the beginning serotypes 2 and 9 and then, from 2002, 4 and 16. To reduce direct losses due to disease and indirect losses due to new serotype circulation, the 2004 Italian vaccination campaign included the modified-live vaccines against BTV-4 and 16 produced by Onderstepoort Biological Product (OBP), South Africa. Few months after the end of the campaign, BTV-16 was reported broadly in the country and the need of differentiating field from the BTV-16 vaccine isolate became crucial. In this study, the gene segments 2, 5, 6 and 10 of both the Italian and vaccine BTV-16 strains were sequenced and their molecular relationship determined. As sequences of segment 5 were those showing the highest differences (17.3%), it was possible to develop a new diagnostic tool able to distinguish the Italian BTV-16 NS1 gene from that of the homologous vaccine strain. The procedure based on the use of a RT-PCR and the subsequent sequencing of the amplified product showed a high degree of sensitivity and specificity when samples from either BTV-16 vaccinated or infected sheep were tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713688     DOI: 10.1016/j.vetmic.2006.03.024

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

1.  Intragenic recombination as a mechanism of genetic diversity in bluetongue virus.

Authors:  Cheng-Qiang He; Nai-Zheng Ding; Mei He; Shan-Ni Li; Xing-Ming Wang; Hong-Bin He; Xin-Fa Liu; Hong-Shan Guo
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

2.  Genetic characterization of bluetongue virus serotype 9 isolates from India.

Authors:  Pavuluri Panduranga Rao; Y Vishnuvardhan Reddy; Keerti Meena; N Karunasree; B Susmitha; Madala Uma; P U V S Prasad; P Chaitanya; Y Narsimaha Reddy; Nagendra R Hegde
Journal:  Virus Genes       Date:  2012-01-19       Impact factor: 2.332

3.  Evidence of bluetongue virus serotype 21 (BTV-21) divergence.

Authors:  B Susmitha; D Sudheer; Pavuluri Panduranga Rao; Madala Uma; Gaya Prasad; P Minakshi; Nagendra R Hegde; Y Narasimha Reddy
Journal:  Virus Genes       Date:  2012-02-18       Impact factor: 2.332

4.  Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains.

Authors:  Sushila Maan; Narender S Maan; Piet A van Rijn; René G P van Gennip; Anna Sanders; Isabel M Wright; Carrie Batten; Bernd Hoffmann; Michael Eschbaumer; Chris A L Oura; Abraham C Potgieter; Kyriaki Nomikou; Peter P C Mertens
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 5.  Bluetongue Virus in France: An Illustration of the European and Mediterranean Context since the 2000s.

Authors:  Cindy Kundlacz; Grégory Caignard; Corinne Sailleau; Cyril Viarouge; Lydie Postic; Damien Vitour; Stéphan Zientara; Emmanuel Breard
Journal:  Viruses       Date:  2019-07-23       Impact factor: 5.048

6.  Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment.

Authors:  Andrew E Shaw; Maxime Ratinier; Sandro Filipe Nunes; Kyriaki Nomikou; Marco Caporale; Matthew Golder; Kathryn Allan; Claude Hamers; Pascal Hudelet; Stéphan Zientara; Emmanuel Breard; Peter Mertens; Massimo Palmarini
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

7.  Bluetongue virus infection induces aberrant mitosis in mammalian cells.

Authors:  Andrew E Shaw; Anke Brüning-Richardson; Ewan E Morrison; Jacquelyn Bond; Jennifer Simpson; Natalie Ross-Smith; Oya Alpar; Peter P C Mertens; Paul Monaghan
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099

Review 8.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.